Join Our Triple O Research Newsletter And Stay Informed.
Triumeq is now FDA approved!
In the past month, The Food and Drug Administration of the United States approved Triumeq (dolutegravir/abacavir/lamivudine).
Triumeq is GlaxoSmithKline’s first single tablet regimen (STR) for the treatment of HIV.
Triumeq is the fourth single tablet regimen currently on the market. Certain patients with a history of HIV have the option to take 1 tablet per day for the treatment of HIV which is dramatically less than 9 to 12 pills per day only 10 years ago!
If you are interested in learning more about Triumeq or the other STR available (Stribild, Complera and Atripla), please inquire with your healthcare provider today!